EQS-News: Geovax reply to the third statement of MPOX as a public health emergency in international concern | 27.02.25

Geovax that advances the vaccine candidate against Geo-MVA to strengthen the overall supply options

Atlanta, GA – February 27, 2025 (Newmediawire) – Geovax Labs, Inc. (Nasdaq: Govx) commented on today’s World Health Organization (WHO) statement about MPOX. In his statement, the WHO reaffirmed the severity of the Mpox epidemic, issuing the third statement within six months from MPOX as an emergency of public health (pheic). This follows the initial statement of August 14, 2024, and the second on November 22, 2024, emphasizing the persistent and escalant nature of the outbreak.

The WHO statement comes as MPOX cases, including the 1B more virulent and transmissible classes, continues to burst globally, with the geographical expansion of its expansion. Starting with 2022, almost 128,000 MPOX cases have been reported in 130 countries. The Democratic Republic of Congo (RDC) was particularly difficult after reporting over 60,000 cases and 1,300 deaths in 2024.

1 MPOX buildings has now spread beyond Africa with cases reported in France, Germany, India, Sweden, Thailand, UK, Canada, USA and other nations. In the United States, Case 1 Mpox cases have now been confirmed in New York, California, Georgia and New Hampshire, raising significant concerns about continuous spread. These cases underline the increasing risk of internal outbreaks and the urgent need for extended access and preparation of the vaccine.

Vaccine supply challenges persist as outbreaks grow

Despite the clear global threat, the offer of vaccines remains critically insufficient:

• Severe lack – African health agencies requested 20 million doses in 2025, however, only 2-5 million doses are expected to be available.
• Addiction to a single source – The world remains very dependent on a single non-American manufacturer for the preferred MPOX vaccine, representing risks of supply chain interruptions.
• High costs and access limitations – In some regions, the preferred Mpox vaccine remains excessively expensive, restricting vaccination efforts, especially in lower revenue regions.

Geovax Geo-MVA: A critical potential solution for the MPOX vaccine supply crisis

Geovax actively addresses these challenges with the development of Geo-MVA, his candidate for the Mpox vaccine. Geovax has successfully manufactured and launched the first clinical batch of geo-MVA drugs, with the filling/finishing and release of the expected clinical product for the middle of the year, supporting the planned initiation of the clinical evaluation of Geo-MVA in the second half of this year.

Geo-MVA, in collaboration with the Geovax Implementation Development Program

• The extended manufacturing capacity at lower costs – The advanced manufacturing process MVA is aimed at establishing a higher yield, an increased production capacity with lower production costs.
• US -based production – Geo-MVA can be manufactured internally, reducing dependence on foreign supply chains and improving biosecurity.

Geovax has strategic partnerships with Oxb (France) and probiogen (Berlin) to support the extension of production and work closely with regulatory agencies to accelerate approval and to ensure a fair vaccine distribution.

A call to action: strengthening the global response

With the latest emergency statement confirming the continuous and growing global threat of MPOX, an immediate action is required:

• Accelerated Geo-MVA and advanced MVA manufacturing process to support a global vaccine growth.
• Extend the policy and funding assistance for alternative sources of vaccines.
• Improve collaboration with global health agencies to ensure vaccine equity, especially in underestimated regions.

“Today’s WHO announcement highlights the urgency of extending the supply of MPOX vaccines and ensuring fast response capacities,” said David Dodd, president and CEO of Geovax. “Geovax remains employed to strengthen global training through Geo-MVA and our efforts to establish an advanced MVA manufacturing process, offering a scalable, accessible and internally produced solution to combat this in progress.”

About Geovax

Geovax Labs, Inc. It is a clinical biotechnology company that develops new vaccines for many of the most threatening infectious diseases in the world for solid tumor cancers. The main clinical program of the company is Geo-CM04S1, a Covid-19 next generation vaccine for which Geovax recently received a Barda funded contract to sponsor a clinical study of 10,000 participants in phase 2B to evaluate the effectiveness of Geo-CM04S1 compared to an approved Covid-19 vaccine. In Addition, Geo-CM04S1 is Currently in Three Phase 2 Clinical Trials, Being Evalated AS (1) A primary Vaccine for Immunocompromised Patients Sufters suffering from Hematological Cancers and Other Patient Populations for Whom the Current Authorized Covid -9 Vaccines has insufficient (2) (2) (2) Booster Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) and (3) to more robust, Durable Covid-19 Booster among healthy patients who have previously received MRNA vaccines. In oncology, the main clinic program evaluates a new therapy directed by solid oncolitic tumor genes, Gedeptin®, after recently completed a 1/2 multicentric phase clinical study for advanced head and neck cancers. A clinical study in phase 2 is planned in the first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune control point inhibitor. Geovax has a strong IP portfolio in support of its product technologies and candidates, having worldwide rights for its technologies and products. The company has a management team that has determined the significant creation of value on several life science companies in the last few decades. For more information on the current state of our clinical studies and other updates, visit our website: www.geovax.com.

Prospective statements

This version contains prospective statements about Geovax’s business plans. The words “believe”, “looking forward”, “more”, “estimation”, “continues”, “anticipate”, “intends”, “should”, “plan”, “could”, “target”, “potential”, “it is probably”, “will”, “wait” and as much as possible, as they are. We have based these prospective statements largely on our current expectations and projections about future events and financial tendencies that we believe can affect our financial status, operations results, business strategy and financial needs. The real results may differ significantly from those included in these statements due to a variety of factors, including if: Geovax is able to achieve acceptable results from the current or future clinical studies, the immuno-oncological products of the Geovax and the preventive vaccines can cause the desired answers, and these products or vaccines can be used in a viag. Technology can amplifies Amplies Amplies Imunes to antigens, geovax can amplified amplifies immunes to antigens, geovax can amplified amplifies immunes to antigens, geovax can amplies responsibly immunes to antigens, geovax can amplifies amplifies responsive IMMAN DEVELOP AND Manufacture Its Immuno-Oncology Products and Preventative Vaccines with the Desired Characteristics in A Timely Manner, Geovax’s Immuno-Oncology Products and Preventative Vaccines Will Be Safe for Human Us Immuno-Oncology Products and Preventative Vaccines Will Receive Regulatory Aprovals Necessary to Be License and Marketed, Geovax Raises Required Capital to complete development, there are development of competitive products that can be more efficient or easier to use than Geovax products, Geovax will be able to conclude favorable manufacturing and other factors, and distribution and distribution. Geovax has no control.

Additional information about our risk factors is contained in our periodic reports on form 10-Q and the 10-K form we have submitted and we will submit to the sec. Any prospective statement made by us here speaks only from the date it is made. The factors or events that could make our real results differ from time to time and it is not possible to predict them all. We assume no obligation to publicly update any prospective statement, either as a result of new information, future or other evolutions, unless they can be requested by law.

Company contact:
[email protected]
678-384-7220

Relationships with Investors Contact:
[email protected]
212-698-8696

Media contact:
[email protected]
202-779-0929

View the original version on www.newmediawire.com

News source: Geovax, Inc.